Micreos develops new biological therapies based on phage & endolysin technology. The company is the developer of Staphefekt, an endolysin that selectively kills Staphylococcus aureus bacteria. Micreos’ Staphefekt SA.100 is an enzyme (endolysin), which kills only Staphylococcus aureus, including MRSA. It is suitable for daily maintenance therapy, for inflammatory skin conditions such as eczema, rosacea, psoriasis, and inflammatory acne and has already had a life-changing impact on thousands of people.
The company is considered the leader in this field. It developed the world’s first endolysin-based products for human health, marketed under the Gladskin brand which targets inflammatory skin conditions and its technology was chosen as Europe’s most impactful innovation in 2018.
Under the PhageGuard brand, Micreos has also developed FDA-approved food safety products against Salmonella and Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised.